Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer

被引：0
|
作者：
Wang, Q. [1 ]
Ma, C. [2 ]
Wang, T. [3 ]
Chen, G. [4 ]
Wang, H. [5 ]
Mei, J. [6 ]
机构：
[1] Henan Canc Hosp, Dept Resp Med, Zhengzhou, Peoples R China
[2] Henan Prov Hosp Tradit Chinese Med, Dept Canc, Zhengzhou, Peoples R China
[3] Henan Univ Tradit Chinese M, Affiliated Hosp 1, Dept Canc, Zhengzhou, Peoples R China
[4] First Peoples Hosp Shangqiu, Dept Canc, Shangqiu, Peoples R China
[5] Anyang Canc Hosp, Dept Canc, Anyang, Peoples R China
[6] Peoples Hosp Zhengzhou, Dept Canc, Zhengzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1119P
引用
收藏
页码：S1063 / S1063
页数：1
相关论文
共 50 条
  • [1] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer
    Shang, X. Q.
    Wang, T.
    Chen, G.
    Ma, C.
    Wang, H.
    Jia, X.
    Mei, J.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1550 - S1550
  • [2] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer: Updated
    Wang, Q.
    Xu, A.
    Ma, C.
    Wang, T.
    Liu, P.
    Duan, Y.
    Kong, T.
    Chen, G.
    Jia, X.
    Shang, K.
    Yang, G.
    Zhang, G.
    Yu, F.
    Wang, H.
    Chen, H.
    [J]. ANNALS OF ONCOLOGY, 2023, 34
  • [3] Combination of Anlotinib and PD-1/PD-L1 Inhibitors as Second-line and Subsequent Therapy in Advanced Small-cell Lung Cancer
    Yu, L.
    Xu, J.
    Qiao, R.
    Zhong, H.
    Han, B.
    Zhong, R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S391 - S392
  • [4] Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer
    Yu, Lian
    Xu, Jianlin
    Qiao, Rong
    Han, Baohui
    Zhong, Hua
    Zhong, Runbo
    [J]. CANCER MEDICINE, 2023, 12 (05): : 5372 - 5383
  • [5] Real-World Efficacy of First-Line Pembrolizumab in Patients with Advanced PD-L1 High Non-Small Cell Lung Cancer in Argentina
    Kuzminin, A.
    Minatta, N.
    Bluthgen, M.
    Rizzo, M.
    Naveira, M.
    Wainsztein, V.
    Lupinacci, L.
    Rizzi, M.
    Faura, M.
    Perfetti, A.
    Recondo, G., Jr.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S589 - S590
  • [6] Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
    La-Beck, Ninh M.
    Nguyen, Dung T.
    Le, Alex D.
    Alzghari, Saeed K.
    Trinh, Saralinh T.
    [J]. PHARMACOTHERAPY, 2020, 40 (03): : 239 - 255
  • [7] Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors
    Peng Song
    Jingcheng Zhang
    Congcong Shang
    Li Zhang
    [J]. Scientific Reports, 9
  • [8] Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors
    Song, Peng
    Zhang, Jingcheng
    Shang, Congcong
    Zhang, Li
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [9] PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
    Isla, Dolores
    Sanchez, Alfredo
    Casal, Joaquin
    Cobo, Manuel
    Majem, Margarita
    Reguart, Noemi
    Zugazagoitia, Jon
    Bernabe, Reyes
    [J]. JOURNAL OF CLINICAL MEDICINE, 2023, 12 (15)
  • [10] Real-World longitudinal practice patterns in the use of PD-1 and PD-L1 inhibitors as First-Line therapy in patients with Non-Small cell lung cancer in the United States
    Veluswamy, Rajwanth
    Hirsch, Fred R.
    Taioli, Emanuela
    Wisnivesky, Juan
    Strauss, Ross
    Harrough, Douglas
    Tang, Boxiong
    Barnes, Gisoo
    [J]. CANCER MEDICINE, 2022, 11 (22): : 4265 - 4272
12345